Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 18/20 | 0.57 |
| ▸ | SMARCA2 | P51531 | 15/20 | 0.57 |
| ▸ | SMARCA4 | P51532 | 15/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23037229 | 0.90 | PBRM1 (0.59) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL30275688 | 0.88 | PBRM1 (0.61) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL26147988 | 0.88 | PBRM1 (0.61) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL31065079 | 0.86 | PBRM1 (0.62) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL23037287 | 0.86 | PBRM1 (0.62) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL26364101 | 0.84 | PBRM1 (0.59) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL22777146 | 0.84 | SMARCA2 (0.46) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL23037256 | 0.83 | PBRM1 (0.70) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL26147502 | 0.83 | PBRM1 (0.69) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL22959811 | 0.82 | PBRM1 (0.60) | PBRM1SMARCA2SMARCA4NR1I2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | PBRM1 37/4885SMARCA2 3/4885SMARCA4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.